Prognostic and Predictive Value of CpG Island Methylator Phenotype in Patients with Locally Advanced Nonmetastatic Sporadic Colorectal Cancer

Table 2

Univariate and multivariate analysis of the prognostic effect of CIMP status and clinicopathological features in stage II/III cases for DFS.

	Univariate analysis			Multivariate analysis^b
	No.	5 yr DFS	𝑃 value	HR	95% CI	𝑃 value
Age (yr)			0.182
≤55	30	69.7%
>55	20	55.0%
Sex			0.990
Male	23	64.6%
Female	27	63.0%
Stage			0.049			0.242
II	18	83.3%		1	reference
III	32	52.9%		3.075	(0.468–20.205)
Site^a			0.092
Proximal	10	40.0%
Distal	40	69.6%
Histology			0.671
Adenocarcinoma	39	66.7%
Mucinous	11	53.0%
Grade			0.681
Well/moderate	36	66.7%
Poor	14	56.3%
CEA level			0.304
Normal	38	56.3%
Elevated	9	44.4%
Adjuvant chemotherapy			0.849
Not received	14	71.4%
Received	36	61.0%
CIMP epigenotype			0.014			0.019
Negative	38	73.7%		1	reference
Positive	12	31.3%		2.935	(1.193–7.220)

5-yr DFS: five-year disease-free survival, CIMP: CpG island methylator phenotype, CEA: carcinoembryonic antigen, HR: hazard ratio.
^aProximal location included the cecum, ascending colon, hepatic flexure of colon, and transverse colon while distal location included the splenic flexure of colon, descending colon, sigmoid colon, and rectum.
^bOnly factors which showed significant impact on DFS in the univariate analysis were included in the Cox regression analysis.